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General introduction 
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      Mammary gland tumor (MGT) is one of the most common tumors in female dogs. The 
survey in a population of over 80,000 insured female dogs indicated that overall-incidence of 
111 per 10,000 dog-years was at risk (Egenvall et al., 2005). Approximately a half of all tumors 
in female dogs is MGT, and a half of MGTs is diagnosed as malignant (Brodey et al., 1983; 
Gilbertson et al., 1983). Among various types of canine MGTs (cMGTs), inflammatory 
mammary carcinoma (cIMC) is extremely malignant, due to its high potentials of invasion to 
surrounding tissues and of metastasis to various organs, including lung, heart, spleen, liver, 
urinary bladder, lymph node and brain (Clemente et al., 2010a; Kim et al., 2011; Marconato et 
al., 2009; Peña et al., 2003; Pérez-Alenza et al., 2001). Canine mammary gland carcinoma with 
inflammatory symptoms is clinically diagnosed as cIMC, and its histopathological feature is the 
emboli of lymphatic vessels with tumor cells (Fig. 0). Mean survival time in dog with cIMC 
was about 50 days after diagnosis (Marconato et al., 2009; Pérez-Alenza et al., 2001; Souza et 
al., 2009). 
      Dogs with cIMC are similar to cases of human inflammatory breast cancer (hIBC) (Peña 
et al., 2003). Human IBC is rare but highly aggressive and cancer cells of hIBC also embolized 
lymphatic vessels in the skin of the breast. Median survival time of hIBC was less than 4 years 
and the 5-year-survival rate was reported to be 34% in the survey from 1988 to 2001 in U.S.A. 
(Anderson et al., 2005). The guideline of diagnosis and treatment for hIBC was issued in the 
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International Conference of Inflammatory Breast Cancer (Dawood et al., 2011). Following the 
guideline, patients with hIBC are recommended systemic chemotherapy for the primary 
treatment. If the size of tumor is reduced, then radical mastectomy is performed and following 
adjuvant radiation therapy is recommended.  
In contrast, chemotherapy, surgery and radiation were reported to be less effective for 
cIMC (Marconato et al., 2009; Souza et al., 2009). Marconato et al. reported that the mean 
survival times of cIMC patients with and without medical treatments were 24 and 80 days, 
respectively. They also reported the survival times of three cIMC dogs treated surgery were 40, 
264 and 278 days, respectively. 
     The epithelial–mesenchymal transition (EMT) is a complex biological process by 
which the morphology of polarized epithelial cells is converted to fibroblastic mesenchymal 
cells. This phenomenon has been known to occur during embryonic development and fibrosis 
(Lamouille et al., 2014; Nakaya and Sheng, 2013; Thiery et al., 2009). Several cycles of EMT 
and mesenchymal-epithelial transition (MET), the reverse process of EMT, are essential for 
final differentiation of internal organ formation (Lamouille et al., 2014; Nakaya and Sheng, 
2013; Thiery et al., 2009). During EMT-MET cycle, primary EMT occurs at gastrulation phase; 
secondary EMT occurs in somites to generate mesenchymal cells with more restricted 
differentiation potential, and final EMT works on heart development (Thiery, 2002).  
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     Recently, EMT was reported to be involved in cancer invasion and metastasis process 
(Kalluri and Weinberg, 2009; Tsuji et al., 2009). Induction of EMT is evaluated by the 
down-regulation of epithelial markers, such as E-cadherin, cytokeratin and ZO-1 (Kalluri and 
Weinberg, 2009) and by the up-regulation of mesenchymal markers, such as vimentin and 
fibonectin (Kokkinos et al., 2007; Olmeda et al., 2007). For example, the expression of 
E-cadherin changes in both degree and localization during EMT, leading to weakened cell-cell 
adhesion interactions (Morali et al., 2001). Cytokeratin and vimentin were reported to be 
down-regulated and up-regulated in breast carcinoma patients with micro metastasis, 
respectively (Willipinski-Stapelfeldt et al., 2005). Localization of ZO-1 was reported to shift 
from cell surface to cytoplasm and nuclear during EMT (Polette et al., 2007). UP-regulation of 
fibronectin was reported in breast cancer patients with metastasis (Fernandez-Garcia et al., 
2014). 
     EMT was reported to be regulated by various growth factors and cytokines (Brown et 
al., 2004; Fernando et al., 2011; Fuxe and Karlsson, 2012; Kamitani et al., 2011; Li et al., 2011; 
Miettinen et al., 1994; Nicolás et al., 2003; Xu et al., 2009). Among them, transforming growth 
factor beta (TGF-β) was reported to be one of the key factors that induces EMT with several cell 
lines (Xu et al., 2009). For instance, TGF-β was reported to induce the morphological change, 
down-regulation of E-cadherin and up-regulation of fibronectin in mouse mammary gland 
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epithelial cell (Miettinen et al., 1994). However, TGF-β was also reported to induce EMT only 
in 2 of the 18 cell lines in one study (Brown et al., 2004). Other factors such as tumor necrosis 
factor alpha (TNF-α) and interleukin 6 (IL-6), were also reported to induce EMT in some cell 
lines. TNF-α was reported to induce the morphological change, down-regulation of E-cadherin 
and up-regulation of vimentin in human prostate cancer cell (Wang et al., 2013a). IL-6 was 
reported to induce the morphological change, down-regulation of E-cadherin and up-regulation 
of vimentin in human head and neck tumor cell (Yadav et al., 2011). 
      Inflammation is also an important factor for tumor progression (Balkwill, 2006; Balkwill 
and Mantovani, 2001; Diakos et al., 2014; Yang and Wolf, 2009). Inflammatory cytokines were 
reported to affect tumor progressions in various tumors (Balkwill, 2006; Balkwill and 
Mantovani, 2001; Ben-Baruch, 2003). Secretions of TNF-α, IL-8 and interleukin 10 (IL-10) 
were detected from tumor associate macrophages in hIBC patients. These inflammatory 
cytokines induced morphological changes and promoted migration and invasion in hIBC cell 
line (Mohamed et al., 2014). Furthermore, gene activations of NF-κB related gene which 
suggested to be involved in EMT, were reported to be higher in hIBC patients than in non-hIBC 
(Lerebours et al., 2008). Thus hIBC is thought to have close relationship with inflammation 
inducing EMT. 
      Based on above, there formed the hypothesis that inflammation and EMT induced by 
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inflammation affected the malignancy of cMGT. To prove the hypothesis, the following study 
was performed. The expressions of EMT markers were compared to evaluate the difference of 
EMT between cIMC and non-cIMC in chapter 1. In chapter 2, canine recombinant TGF-β, 
TNF-α and IL-6 were purified and examined their availability for the following study. In chapter 
3, six cMGT cell lines were stimulated with canine recombinant proteins to investigate whether 
EMT was induced (section 1). In section 2 of chapter 3, MGT cell line was cloned for further 
investigations. The clonal cells which were sensitive to inflammatory stimulations and had the 
most epithelial-like feartures, were stimulated by cytokines and evaluated for expression 
changes of EMT markers. In chapter 4, clonal cells which selected in chapter 3 were 
subcutaneously injected into nude mice and stimulated with cytokines to investigate whether 
inflammatory stimulations induced EMT and affected tumor malignancy in vivo.  
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Fig 0 Canine inflammatory carcinoma. 
Dogs with cIMC exhibit inflammatory symptoms such as redness, edema, hot feeling and pain 
(a).  The histopathological feature of cIMC is the emboli of tumor cells in lymphatic vessels 
with hematoxylin-eosin stain (b). 
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Chapter 1 
 
 
Evaluation of epithelial-mesenchymal transition in canine 
inflammatory and non-inflammatory mammary 
carcinomas 
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本章の内容は、学術雑誌論文として投稿する計画があるため公表できない。 
５年以内に出版予定。 
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Chapter2 
 
 
Investigation of the ability of canine recombinant 
inflammatory cytokines to induce EMT in MDCK cells 
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2.1 Introduction 
 In the previous chapter, cIMC showed stronger EMT change in comparison to 
non-cIMC. EMT has been reported to be regulated by various growth factors and cytokines 
(Brown et al., 2004; Fernando et al., 2011; Fuxe and Karlsson, 2012; Kamitani et al., 2011; Li et 
al., 2011; Miettinen et al., 1994; Nicolás et al., 2003). For example, TGF-β induced EMT in 
mouse mammary gland epithelial cells (Miettinen et al., 1994). In this report, morphological 
change and reduction of E-cadherin and ZO-1 were reported. Co-stimulation of TGF-β and 
TNF-α was reported to induce morphological change and vimentin expression in bronchial 
epithelial cells (Kamitani et al., 2011). IL-6 was reported to induce morphological change and 
expression change of E-cadherin and vimentin in head and neck tumor cell (Yadav et al., 2011). 
As cIMC exhibits inflammatory clinical signs, EMT in cIMC was thought to be affected by 
these factors, especially inflammatory cytokines. For further investigation of relationship 
between malignancy of cMGT and inflammation inducing EMT, it is important to reveal the 
role of inflammatory cytokines during EMT. 
 In veterinary medicine, human recombinant TGF-β is known to induce EMT in 
Madin-Darby canine kidney (MDCK) cells (Moyano et al., 2010; Zhang et al., 2006), but it 
remains unclear whether inflammatory cytokines can induce EMT in this cell line. Cross 
reactivity of cytokines differed with each cytokines (Just et al., 1991; Vieira et al., 1991). 
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Additionally, homology between human gene and canine gene of these cytokines is not so high. 
To investigate EMT in dogs accurately, construction and purification of canine recombinant 
cytokine was thought to be needed. 
 The purpose of this chapter was to construct and purify canine recombinant TGF-β, 
TNF-α and IL-6 for the studies of following chapter. Their effects of EMT induction on MDCK 
cells were evaluated by changes of E-cadherin expression and cell morphology. 
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2.2 Materials and methods 
2.2.1 Cell culture 
 MDCK cells were kindly provided by Associate Professor Horimoto at the University 
of Tokyo and were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Wako, Osaka, 
Japan) containing 5% fetal bovine serum (FBS). Canine mammary gland tumor cell line, CHMp 
(Uyama et al., 2006), cells were cultured in RPMI1640 containing 10% FBS. These cells were 
maintained in a humidified atmosphere of 5% CO2 at 37°C. 
 
2.2.2 RNA isolation 
 Canine RNA was extracted from CHMp cells using TRI Reagent (Molecular Research 
Center Inc., OH, USA) according to the manufacturer’s instructions. Canine macrophage RNA 
was kindly provided by Professor Tsujimoto at the University of Tokyo (Goto-Koshino et al., 
2011). 
 
2.2.3 Expression and purification of cTGF-β, cTNF-α, and cIL-6 
 cDNA of cTGF-β was amplified by reverse transcription-polymerase chain reaction 
(RT-PCR) from canine RNA extracted from CHMp cells using SuperScript III Reverse 
Transcriptase (Invitrogen, CA, USA). The cDNA of cTNF-α and cIL-6 were amplified from 
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canine RNA extracted from canine macrophages. Primers used in this study are listed in 
Table2.1. Amplified cDNA fragments were cloned into a pGEX-6p-2 vector (GE Healthcare, NJ, 
USA). Escherichia coli BL21 (DE3) cells were grown at 25°C, and protein expression of the 
recombinant plasmids was induced by the addition of 0.1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). For GST and LPS residual control, a pGEX-6p-2 
vector alone and no vector control were transfected with E. coli BL21 cells. E. coli BL21 cells 
were harvested by centrifugation, resuspended, and sonicated in a sonication buffer (40 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and 0.5% Triton X-100). Recombinant proteins 
were purified by affinity chromatography using Glutathione-Sepharose 4 beads (GE Healthcare). 
Proteins bound
 
to the beads were washed with and resuspended
 
in cleavage buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol (DTT)). Next, Pre 
Scission protease
 
(GE Healthcare) was added and the suspension was
 
incubated overnight at 4°C. 
After centrifugation, the first
 
supernatant was collected. Collected supernatants were dialyzed 
against phosphate-buffered saline (PBS). Recombinant proteins were detected by western blot 
analysis. Briefly, solutions of recombinant proteins were used in a mixture of sample buffer 
(100 mM Tris-HCl, pH6.8, 2% sodium dodecyl sulfate (SDS), 12% 2-mercaptoethanol, 20% 
glycerol, and bromophenol blue). Samples were run on 4–15% Mini-PROTEAN TGX gel 
(Bio-Rad Laboratories, CA, USA) and transferred to polyvinylidene fluoride (PVDF) 
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membranes (Bio-Rad). The membranes were then incubated with rabbit anti-TGF-β1 (1:1000; 
LifeSpan Biosciences Inc., WA, USA), rabbit anti-TNF-α (1:500; Abgent, CA, USA), and goat 
anti-canine IL-6 (1:1000; R&D systems, MN, USA), followed by incubation with anti-mouse 
IgG conjugated to horseradish peroxidase (HRP) (1:10,000; GE Healthcare), anti-rabbit IgG 
conjugated to HRP (1:10,000; GE Healthcare), and anti-goat IgG conjugated to HRP 
(1:100,000; Santa Cruz Biotechnology). Signals were detected using the Luminata Forte 
Western HRP substrate (Millipore). The experiment was approved by the Life Science 
Committee of the Graduate School of Agricultural and Lifesciences, the University of Tokyo. 
(Accession number: 541-2323) 
 
2.2.4 Cell stimulation 
 Recombinant cTGF-β, cTNF-α, cIL-6, and GST residues were added to the cells at a 
final concentration of 10 ng/mL and residual LPS control was added at the same dilution of 
cIL-6, minimum dilution ratio.  Cells were incubated at 37 °C for 24 h. Cells were lysed in 
Triton X-100 buffer (0.5% Triton X-100, 2.5 mM EDTA, 5 mM MgCl2, and 50 mM PIPES; pH 
6.2) and collected as soluble fractions. Insoluble cell fractions were washed twice with Triton 
X-100 buffer and then extracted in buffer containing 1% SDS. 
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2.2.5 Immunoblot analysis 
 Cell lysates in sample buffer were used for immunoblot analysis. Samples containing 
10 µg of total protein per lane were subjected to gel electrophoresis and transferred to PVDF 
membranes as described above. The membranes were then incubated with mouse 
anti-E-cadherin antibody (1:2000; BD Biosciences) and mouse anti-actin antibody (1:10,000; 
Millipore), followed by incubation with anti-mouse IgG conjugated to HRP. Signals were 
detected as described above. Quantifications of signals were performed by using ImageJ 
software. 
 
2.2.6 Immunofluorescent staining 
 MDCK cells were stimulated as described in section 2.2.4, and incubated for 6 h and 
24 h. Cells were fixed with 4% paraformaldehyde (PFA) in PBS and blocked with PBS 
containing 10% bovine serum albumin for 1 h. Next, cells were incubated with anti-E-cadherin 
antibody for 1 h, followed by incubation with Alexa 568-conjugated goat anti-mouse IgG 
antibodies (Invitrogen) for 30 min at room temperature. Cells were then washed three times 
with PBS and mounted in DAPI containing Vectashield mounting medium (Vector 
Laboratories). 
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2.2.7 Cell morphology 
 MDCK cells were starved for 24 h, followed by stimulation with recombinant cTGF-β, 
cTNF-α, and cIL-6 at a final concentration of 10 ng/mL in DMEM containing 0.1% FBS, and 
incubated at 37°C for 6 days. Cells were fixed with 4% PFA in PBS and stained with 
Wright-Giemsa stain. 
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2.3 Results 
2.3.1 Purification of cTGF-β, cTNF-α, and cIL-6 
 Recombinant cTGF-β, cTNF-α, and cIL-6 were expressed by E. coli (BL21) cells and 
purified by using Glutathione-Sepharose 4 beads and Pre Scission protease. After cleavage of 
GST fusion recombinant proteins using Pre Scission protease, recombinant cTGF-β, cTNF-α, 
and cIL-6 were isolated (Fig. 2.1). These cytokines were used in the following experiments. 
 
2.3.2 Transition of localization and reductions of E-cadherin expressions 
 At 6 h post-stimulation (p.s.), expression of E-cadherin levels in the insoluble fractions 
were reduced, whereas increased in the soluble fractions except for the stimulation followed by 
TGF-β stimulation. This may represent a shift in the localization of E-cadherin. At 12 h p.s., 
changes in expression patterns were observed in soluble fractions. At 24 h p.s., the total amounts 
of E-cadherin were reduced under all conditions. In addition, co-stimulation caused significant 
down-regulation of E-cadherin expression (Fig. 2.2).  
 Immunofluorescent staining also showed that inflammatory cytokines induced a 
reduction in cell surface E-cadherin (Fig. 2.3). Co-stimulation enhanced this phenomenon, 
particularly following TGF-β /IL-6 stimulation. GST residues and residual LPS had no effect on 
E-cadherin expression (date not shown). 
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2.3.3 Effects of TNF-α on morphology of MDCK cells 
 The morphological change from epithelial to mesenchymal form is one of the most 
essential features of EMT. In this study, cell stimulation induced a decrease in adhesion 
molecules at 24 h after stimulations, but no changes in cell morphology were observed at 24 h. 
However, 6 days after stimulations, morphological changes had occurred. TGF-β and IL-6 did 
not induce the change of cell shape, but TNF-α and TGF-β/TNF-α induced significant 
morphological changes from cobble to spindle forms, and weakened cell-cell adhesion 
interactions (Fig. 2.4). GST residues and residual LPS also had no effect on cell morphology 
(date not shown). 
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2.4 Discussion 
 Most cell stimulation studies on canine cells were carried out using human 
recombinant proteins (Morita et al., 2007; Wang et al., 2013b; Zhang et al., 2006, 2014). 
However, the homology level between human and canine RNA is not high; homology levels 
between TGF-β, TNF-α, and IL-6 RNA are 92%, 91%, and 76%, respectively. Because the 
effects of these disparities were unclear, construction of recombinant proteins derived from dogs, 
cTGF-β, cTNF-α, and cIL-6, was thought to be needed for evaluating EMT in canine cells 
correctly. 
 In this study, cTGF-β, cTNF-α, and cIL-6 were expressed by E. coli (BL21) cells and 
purified successfully. Purified cTGF-β, cTNF-α, and cIL-6 were detected by western blot 
analysis at 13 kDa, 17kDa and 21 kDa, respectively. The possibility of contamination of minor 
residual LPS and GST in purified cytokines existed, because these cytokines were expressed by 
E. coli (BL21) cells using pGEX-6p-2 vector which contained GST coding region. These 
residual LPS and GST did not affect MDCK cells. These cytokines successfully induced EMT 
change in MDCK cells with the concentration of 10 ng/mL. In the pilot study, 1 ng/mL of 
cTGF-β did not induce E-cadherin reduction but 10 ng/mL of cTGF-β sufficiently reduced 
E-cadherin expression. Therefore, these cytokines were suitable for cell stimulations and 
stimulations were performed at 10 ng/mL. 
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 The results obtained in this chapter indicated that the down-regulation and the shift of 
E-cadherin were induced not only by TGF-β, but also by inflammatory cytokines, TNF-α and 
IL-6. E-cadherin was reported to shift its localization from membrane to cytoplasm during EMT 
(Morali et al., 2001). These three recombinant cytokines were suggested to induce EMT in 
MDCK cell. The loss of cell surface E-cadherin was caused by cTGF-β/cTNF-α co-stimulation 
and cTGF-β/cIL-6 co-stimulation at six and twenty four hours post-stimulation, whereas single 
stimulation by cTGF-β, cTNF-α and cIL-6 caused little changes of cell surface E-cadherin 
expressions at these time points. Furthermore, cTNF-α stimulation and cTGF-β/cTNF-α 
co-stimulation induced morphological change of MDCK cells. Co-stimulation of TGF-β and 
inflammatory cytokines such as TNF-α and IL-6 were reported to enhance morphological 
change and expression change of E-cadherin in lung cancer cell lines (Abulaiti et al., 2013; 
Kawata et al., 2012). TGF-β and inflammatory cytokines were suggested to interact with each 
other and enhance the functions of EMT inducing factors. Thus, the inflammatory cytokines 
were thought to be not only inducer of EMT but also enhancer of EMT induced by other 
inducing factor. 
 Loss or reduction of E-cadherin and morphological change of cells were some features 
of EMT. Although these three recombinant cytokines showed partials of EMT phenomena, these 
were thought to be EMT inducible factors. Therefore, in the following chapter, EMT in cMGTs 
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was investigated in vitro and in vivo using these cytokines. 
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Table 2.1 Gene information and primer sequences. 
Recombinant
protein
Accession
number
Primer sequence
Primer
position
Length of PCR
fragment
5′- CGGAATTC CCGCCCTGGACACCAACTA -3′ 892-908
5′- ACGCGTCGAC TCAGCTGCACTTGCAGGA -3′ 1213-1230
5′- CGCGGATCC GTCAAATCATCTTC -3′ 229-242
5′- ACGCGTCGAC TCACAGGGCAATGATTCC -3′ 685-700
5′- CGCGGATCC ATGAACTCCCTCTCCA -3′ 1-16
5′- ACGCGTCGAC TCACATTATCCGAACA -3′ 609-624
cIL-6 AF275796.1 624bp
＊Restriction sites are indicated in italics
cTGF-β L34956.1 239bp
cTNF-α DQ923808 472bp
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Fig. 2.1 Purification of recombinant cTGF-β, cTNF-α, and cIL-6. 
Recombinant cTGF-β, cTNF-α, and cIL-6 were expressed by E. coli (BL21) and purified by 
using Glutathione-Sepharose 4 beads and Pre Scission protease. Recombinant proteins were 
detected by anti-TGF-β1 antibody, anti-TNF-α antibody, and anti-IL-6 antibody. The molecular 
weights of cTGF-β, cTNF-α, cIL-6, and glutathione S transferase (GST) were 13 kDa, 17 kDa, 
21 kDa, and 28 kDa, respectively. 
  
 
13kDa
41kDa
17kDa
45kDa
21kDa
49kDa
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Fig.2.2 Reduction and shift of E-cadherin. 
MDCK cells were stimulated with TGF-β (10 ng/mL), TNF-α (10 ng/mL), and/or IL-6 (10 
ng/mL). After 6 hr, 12 hr, and 24 hr post-stimulation, cells were lysed with Triton X-100 buffer 
or SDS buffer. Expressions of E-cadherin were determined by western blot analysis. After 6 hr 
post-stimulation, localization of E-cadherin shifted from insoluble fraction to soluble fraction. 
After 24 hr post-stimulation, E-cadherin in insoluble fraction was significantly reduced. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig.2.3 Change in the amount of cell surface E-cadherin. 
MDCK cells were stimulated with TGF-β (10 ng/mL), TNF-α (10 ng/ml) and/or IL-6 (10 
ng/mL). Six hours and 24 h post-stimulation, cells were fixed and immunostained with mouse 
anti-E-cadherin antibody, followed by Alexa 568-conjugated goat anti-mouse IgG.  Nuclei 
were stained with DAPI. E-cadherin expression was reduced at the cell surface, especially in 
co-stimulating cells. Red: E-cadherin. Blue: DAPI. 
  
 
Control
TGF-β 
6hr
12hr
24hr
TNF-α 
IL-6
TGF-β/TNF-α 
TGF-β/IL-6 
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Fig.2.4 Morphological changes in MDCK cells. 
MDCK cells were stimulated with TGF-β (10 ng/mL), TNF-α (10 ng/mL), and/or IL-6 (10 
ng/mL). Six days post-stimulation, cells were fixed and stained with Wright-Giemsa stain.  
TGF-β and IL-6 did not substantially change the cell morphology. However, TNF-α and 
TGF-β/TNF-α weakened cell-cell adhesion interactions and induced morphological changes 
from cobble to spindle forms.  
  
 
Control TGF-β TNF-α
IL-6 TGF-β/TNF-α TGF-β/IL-6
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Chapter 3 
 
 
Effects of inflammatory cytokines on EMT marker 
expressions in cMGT cells 
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3.1. Introduction 
 The epithelial–mesenchymal transition (EMT) is a complex biological process by 
which the morphology of polarized epithelial cells is converted to fibroblastic mesenchymal 
cells. EMT in cancer cell has been reported to be induced by various cytokines and related to 
tumor malignancy. For instance, human TGF-β was reported to induce EMT in human breast 
cancer cell (Li et al., 2014) and ovarian cancer cells (Gao et al., 2014).In addition, human 
TNF-α, human IL-6 and human IL-8 were also reported to induce EMT in various cancer cells 
(Fernando et al., 2011; Ho et al., 2012; Rokavec et al., 2014; Wang et al., 2013b). On the other 
hand, it has been well known that inflammation in microenvironment affects the growth of 
tumor (Coussens et al., 2013). As one of the distinguish feature of cIMC is severe inflammation 
associated with tumor mass, it is suspected that the inflammation has close relationship with the 
malignancy of cIMC. Actually, amount of infiltrations of tumor associate macrophage and 
secretions of TNF-α, IL-8 and IL-10 in hIBC patients were higher than in non-hIBC patients 
(Mohamed et al., 2014). These inflammatory cytokines were also reported to promote morphological 
change, cell migration and invasion in hIBC cell lines (Mohamed et al., 2014). Because clinical 
features of cIMC are similar to those of hIBC, it was hypothesized that inflammatory 
stimulation by various cytokines in the tumor microenvironment contributed the malignancy of 
cIMC through induction of EMT. 
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 The purpose of this chapter was to investigate whether canine TGF-β, TNF-α and IL-6, 
which were successfully obtained in the previous chapter, induced EMT in cMGT cell lines by 
the evaluation of EMT marker expressions. In section 1, to evaluate the effects of inflammatory 
cytokines on cMGT cell, six cMGT cell lines were stimulated with cytokines and investigated 
whether the expression changes of EMT markers were induced by inflammatory stimulation. 
For further investigation, cMGT cell line was cloned and a clonal cell line was stimulated with 
cytokines to investigate effects of inflammatory stimulation in section 2. 
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Section 1: Expression changes of EMT markers in cMGT cell lines stimulated with 
cTGF-β, cTNF-α and cIL-6 
3.1.2 Materials and methods 
3.1.2.1 Cell culture 
 Canine MGT cell lines, CHMp, CHMm, CTBp, CTBm, CIPp and CIPm cell (Uyama 
et al., 2006) were used in this section (Table 3.1.1). Cells were cultured in RPMI1640 
containing 10% FBS at a humidified atmosphere of 5% CO2 and 37°C. 
 
3.1.2.2 Reagent 
 Canine recombinant proteins, cTGF-β, cTNF-α and cIL-6, prepared as described in 
chapter 2 were used. 
 
3.1.2.3 Cell stimulation 
 Six cMGT cell lines were stimulated with recombinant cTGF-β, cTNF-α and cIL-6 
singly or coincidentally at a final concentration of 10 ng/mL. Stimulated cells were harvested at 
24 hours post simulation. 
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3.1.2.4 Immunoblot analysis 
 Cell lysates were collected as described in chapter 2. Lysates of insoluble fraction of 
stimulated cells were used in a mixture of sample buffer (100 mM Tris-HCl, pH6.8, 2% sodium 
dodecyl sulfate (SDS), 12% 2-mercaptoethanol, 20% glycerol, and bromophenol blue). Samples 
were containing 10 µg of total protein per lane, and run on 4–15% Mini-PROTEAN TGX gel 
(Bio-Rad), then transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad). The 
membranes were then incubated with mouse anti-E-cadherin antibody (1:2,000; BD 
Biosciences), rabbit anti-ZO-1 (1:2,000; Santa Cruz Biotechnology), mouse anti-vimentin 
(1:2,000; Millipore), mouse anti-N-cadherin (1:2,000; Abcam), rabbit anti-fibronectin (1:5,000; 
Dako Japan) and mouse anti-actin antibody (1:10,000; Millipore), followed by incubation with 
anti-mouse IgG conjugated to horseradish peroxidase (HRP) (1:10,000; GE Healthcare) and 
anti-rabbit IgG conjugated to HRP (1:10,000; GE Healthcare). Signals were detected using the 
Luminata Forte Western HRP substrate (Millipore). Quantifications of signals were performed 
by using ImageJ software. 
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3.1.3 Results 
 EMT marker expression patterns of non-stimulated cell were similar within CIP pair 
and not within CHM and CTB pairs. Difference expression patterns of EMT marker between 
CHMp and CHMm were E-cadherin, N-cadherin and ZO-1 (Fig. 3.1.1 and Fig. 3.1.2). 
Difference expression patterns of EMT marker between CTBp and CTBm were E-cadherin and 
N-cadherin (Fig. 3.1.3 and Fig. 3.1.4).Similar expression patterns of EMT marker between CIPp 
and CIPm were E-cadherin, N-cadherin, fibronectin and vimentin (Fig. 3.1.5 and Fig. 3.1.6).  
 Six cell lines of cMGT were stimulated with cTGF-β, cTNF-α and cIL-6. Expression 
changes of EMT markers were varied among these cell lines. In CHMp cells, expressions of 
ZO-1 were down-regulated by cTNF-α and cTGF-β/cIL-6 stimulations, and up-regulated by 
cIL-6 and cTGF-β/cTNF-α stimulations. Expressions of N-cadherin were up-regulated by 
cTGF-β, cTNF-α and cIL-6 stimulations. Expressions of fibronectin were down-regulated by all 
stimulations. Expressions of vimentin were down-regulated by all stimulations except cTGF-β 
stimulation. (Fig. 3.1.1). In CHMm cells, expressions of E-cadherin were up-regulated by 
cTNF-α and cIL-6 stimulations. Expressions of ZO-1 were down-regulated by cTGF-β, cIL-6 
and cTGF-β/cTNF-α stimulations, and up-regulated by cTNF-α stimulation. Expressions of 
fibronectin were down-regulated by cTNF-α, cIL-6 and cTGF-β/cIL-6. Expressions of vimentin 
were down-regulated by all stimulations (Fig. 3.1.2). In CTBp cells, expressions of E-cadherin 
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were down-regulated by all stimulations except cTGF-β stimulation. Expressions of ZO-1 were 
up-regulated by all stimulations except cTGF-β/cTNF-α stimulation. Expressions of fibronectin 
were up-regulated by all stimulations except cTGF-β stimulation. Expressions of vimentin were 
down-regulated by all stimulations (Fig. 3.1.3). In CTBm cells, expressions of E-cadherin were 
down-regulated by all stimulations except cTGF-β stimulation, and up-regulated by cTGF-β 
stimulation. Expressions of ZO-1 were down-regulated by all stimulations except cTGF-β 
stimulation. Expressions of fibronectin were up-regulated by cTGF-β and cTGF-β/cIL-6 
stimulations, and down-regulated by cTNF-α, cIL-6 and cTGF-β/cTNF-α stimulations. 
Expressions of vimentin were down-regulated by cTNF-α, cIL-6 and cTGF-β/cTNF-α 
stimulations (Fig. 3.1.4). In CIPp cells, expressions of E-cadherin were down-regulated by all 
stimulations except cTGF-β stimulation. Expressions of ZO-1 were up-regulated by 
cTGF-β/cTNF-α stimulation. Expressions of N-cadherin were down-regulated by cTNF-α 
stimulation. Expressions of vimentin were up-regulated by cTGF-β/cIL-6 stimulation (Fig. 
3.1.5). In CIPm cells, expressions of E-cadherin were down-regulated by cTGF-β, cTNF-α and 
cTGF-β/cTNF-α stimulations, and up-regulated by cTGF-β/cIL-6 stimulation. Expressions of 
ZO-1 were up-regulated by all stimulations. Expressions of N-cadherin were up-regulated by 
cTGF-β/cTNF-α stimulation, and down-regulated by cIL-6 stimulation. Expressions of 
fibronectin were up-regulated by cIL-6 and cTGF-β/cTNF-α stimulations, and down-regulated 
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by cTNF-α and cTGF-β/cIL-6 stimulations. Expressions of vimentin were up-regulated by 
cTGF-β/cTNF-α and cTGF-β/cIL-6 stimulations (Fig. 3.1.6).  
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3.1.4 Discussion 
 In this section, it was investigated whether stimulation with single and combination of 
canine recombinant cytokine TGF-β, TNF-α and IL-6 induced EMT in cMGT cell lines. 
Although IL-6 was reported to induce the decrease in E-cadherin in breast cancer cell lines 
(Sullivan et al., 2009), it was also reported not to show the reaction in other breast cancer cell 
lines (Asgeirsson et al., 1998). These results indicate that the reactivity to cytokine stimulations 
may be different in each cell line. Considering the difference in reactivity of individual cells, six 
cMGT cell lines which derived from primary and metastatic lesions of 3 cases were subjected to 
this study. 
 In CHMp cells, cTGF-β induced EMT change in N-cadherin, and MET change, 
reverse phenomenon of EMT, in fibronectin. Canine TNF-α induced EMT change in ZO-1 and 
N-cadherin, and MET change in fibronectin and vimentin. Canine IL-6 induced EMT change in 
N-cadherin, and MET change in ZO-1, fibronectin and vimentin. Canine TGF-β/cTNF-α 
induced MET change in ZO-1, fibronectin and vimentin. Canine TGF-β/cIL-6 induced EMT 
change in ZO-1, and MET change in fibronectin and vimentin. In CHMm cells, cTGF-β induced 
EMT change in ZO-1, and MET change in vimentin. Canine TNF-α induced MET change in 
E-cadherin, ZO-1, fibronectin and vimentin. Canine IL-6 induced EMT change in ZO-1, and 
MET change in E-cadherin, fibronectin and vimentin. Canine TGF-β/cTNF-α induced EMT 
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change in ZO-1, and MET change in vimentin. Canine TGF-β/cIL-6 induced MET change in 
fibronectin and vimentin. In CTBp cells, cTGF-β induced MET change in ZO-1 and vimentin. 
Both cTNF-α and cIL-6 induced EMT change in E-cadherin and fibronectin, and MET change 
in ZO-1 and vimentin. Canine TGF-β/cTNF-α induced EMT change in E-cadherin and 
fibronectin, and MET change in vimentin. Canine TGF-β/cIL-6 induced EMT change in 
E-cadherin and fibronectin, and MET change in ZO-1 and vimentin. In CTBm cells, cTGF-β 
induced EMT change in fibronectin, and MET change in E-cadherin. Canine TNF-α, cIL-6 and 
cTGF-β/cTNF-α induced EMT change in E-cadherin and ZO-1, and MET change in fibronectin 
and vimentin. Canine TGF-β/cIL-6 induced EMT change in E-cadherin, ZO-1 and fibronectin. 
In CIPp cells, cTNF-α induced EMT change in E-cadherin, and MET change in N-cadherin. 
Canine IL-6 induced EMT change in E-cadherin. Canine TGF-β/cTNF-α induced EMT change 
in E-cadherin, and MET change in ZO-1. Canine TGF-β/cIL-6 induced EMT change in 
E-cadherin and vimentin. In CIPm cells, cTGF-β induced EMT change in E-cadherin, and MET 
change in ZO-1. Canine TNF-α induced EMT change in E-cadherin, and MET change in ZO-1 
and fibronectin. Canine IL-6 induced EMT change in fibronectin, and MET change in ZO-1 and 
N-cadherin. Canine TGF-β/cTNF-α induced EMT change in E-cadherin, N-cadherin, fibronectin 
and vimentin, and MET change in ZO-1. Canine TGF-β/cIL-6 induced EMT change in vimentin, 
and MET change in E-cadherin, ZO-1 and fibronectin. Although cell lines from the same dog 
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showed similar tendency of expression change of EMT markers, effects of cytokines on cMGT 
cell lines were not always constant. As cMGT cell lines used in this study were derived from 
tumor tissues of spontaneous MGT cases and had not been monocloned, these cell lines were 
thought to have heterogeneous cell populations. It was assumed that the accumulation of 
different reactivities of each cell population to cytokine stimuli made the reactivity of each cell 
line diverse. Thus, monoclonal cell line was thought to be suitable for investigation of the 
effects of cytokines. 
 CIPp cell line was estimated to be sensitive to the stimulations comparing to other cell 
lines, because loss or reduce of E-cadherin were induced by cTNF-α, cIL-6, cTGF-β/cTNF-α 
and cTGF-β/cIL-6 stimulations, and acquisition of vimentin were induced by cTGF-β/cIL-6 
stimulation. Therefore, cloning of CIPp cells and evaluation of cell features based on the EMT 
marker expression were conducted to perform in section 2.  
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Table3.1.1 Characters of cMGT cell lines. 
 
  
Cell line Breed Age(years) Diagnosis Clinical stage TNM Origin of tumor
CHMp Mongrel 12 Ⅳ T4N1M1 Primary mass
CHMm Metastatic LN
1
CTBp Mongrel 12 Ⅳ T4N1M0 Primary mass
CTBm Metastatic LN
1
CIPp Shih Tzu 10 Adenocarcinoma Ⅳ T1cN1M1 Primary mass
CIPm Pleural effusion
1
LN, lymph node
Inflammatory
adenocarcinoma
Inflammatory
adenocarcinoma
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Fig. 3.1.1 Western blot of stimulated CHMp cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of ZO-1 were reduced by cTNF-α and cTGF-β/cIL-6 stimulations and increased by 
cIL-6 and cTGF-β/cTNF-α stimulations. Expressions of N-cadherin were increased by cTGF-β, 
cTNF-α and cIL-6 stimulations. Expressions of fibronectin were reduced by all stimulations. 
Expressions of vimentin were reduced by all stimulations except cTGF-β stimulation. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig. 3.1.2 Western blot of stimulated CHMm cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of E-cadherin were increased by cTNF-α and cIL-6 stimulations. Expressions of 
ZO-1 were reduced by cTGF-β, cIL-6 and cTGF-β/cTNF-α stimulations and increased by 
cTNF-α stimulation. Expressions of fibronectin were reduced by cTNF-α, cIL-6 and 
cTGF-β/cIL-6. Expressions of vimentin were reduced by all stimulations. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig. 3.1.3 Western blot of stimulated CTBp cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of E-cadherin were reduced by all stimulations except cTGF-β stimulation. 
Expressions of ZO-1 were increased by all stimulations except cTGF-β/cTNF-α stimulation. 
Expressions of fibronectin were increased by all stimulations except cTGF-β stimulation. 
Expressions of vimentin were reduced by all stimulations. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig. 3.1.4 Western blot of stimulated CTBm cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of E-cadherin were reduced by all stimulations except cTGF-β stimulation and 
increased by cTGF-β stimulation. Expressions of ZO-1 were reduced by all stimulations except 
cTGF-β stimulation. Expressions of fibronectin were increased by cTGF-β and cTGF-β/cIL-6 
stimulations and reduced by cTNF-α, cIL-6 and cTGF-β/cTNF-α stimulations. Expressions of 
vimentin were reduced by cTNF-α, cIL-6 and cTGF-β/cTNF-α stimulations. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig. 3.1.5 Western blot of stimulated CIPp cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of E-cadherin were reduced by all stimulations except cTGF-β stimulation. 
Expressions of ZO-1 were increased by cTGF-β/cTNF-α stimulation. Expressions of N-cadherin 
were reduced by cTNF-α stimulation. Expressions of vimentin were increased by cTGF-β/cIL-6 
stimulation. 
＊: p < 0.05. Vertical bar represents SE. 
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Fig. 3.1.6 Western blot of stimulated CIPm cells in insoluble fractions. 
Cells were stimulated with cTGF-β, cTNF-α and cIL-6 at a final concentration of 10 ng/ml. 
Expressions of E-cadherin were reduced by cTGF-β, cTNF-α and cTGF-β/cTNF-α stimulations, 
and increased by cTGF-β/cIL-6 stimulation. Expressions of ZO-1 were increased by all 
stimulations. Expressions of N-cadherin were increased by cTGF-β/cTNF-α stimulation, and 
reduced by cIL-6 stimulation. Expressions of fibronectin were increased by cIL-6 and 
cTGF-β/cTNF-α stimulations, and reduced by cTNF-α and cTGF-β/cIL-6 stimulations. 
Expressions of vimentin were increased by cTGF-β/cTNF-α and cTGF-β/cIL-6 stimulations. 
＊: p < 0.05. Vertical bar represents SE. 
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Section 2: Expression changes of EMT markers in cloned CIPp-4b cell line stimulated 
with cTGF-β, cTNF-α and cIL-6 
本項の内容は、学術雑誌論文として投稿の計画があるため公表できない。 
５年以内に出版予定。 
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Chapter 4 
 
 
Effects of inflammatory stimulations in the cMGT 
transplanted mouse model 
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本章の内容は、学術雑誌論文として投稿する計画があるため公表できない。 
５年以内に出版予定。 
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Summary 
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本項の内容は、学術雑誌論文として投稿する計画があるため公表できない。 
５年以内に出版予定。 
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